Health Care [ 3/12 ] | Pharmaceuticals [ 9/73 ]
NASDAQ | Common Stock
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases.
It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.
The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Oct 30, 25 | -0.15 Increased by +88.64% | -0.47 Increased by +68.09% |
| Aug 7, 25 | -0.79 Increased by +49.36% | -0.91 Increased by +13.19% |
| May 7, 25 | -1.07 Increased by +24.65% | -1.07 Decreased by -0.38% |
| Mar 5, 25 | -1.05 Increased by +24.46% | -1.08 Increased by +2.78% |
| Nov 7, 24 | -1.32 Decreased by -73.68% | -1.49 Increased by +11.41% |
| Aug 8, 24 | -1.56 Decreased by -85.71% | -1.38 Decreased by -13.04% |
| May 9, 24 | -1.42 Decreased by -59.55% | -1.31 Decreased by -8.40% |
| Mar 7, 24 | -1.39 Decreased by -4.51% | -1.08 Decreased by -28.70% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 49.50 M Increased by +202.74% | -29.97 M Increased by +64.98% | Decreased by -60.55% Increased by +88.43% |
| Jun 30, 25 | 39.50 M Increased by +439.36% | -75.81 M Increased by +17.10% | Decreased by -191.91% Increased by +84.63% |
| Mar 31, 25 | 28.52 M Increased by +1.39 K% | -94.32 M Decreased by -13.84% | Decreased by -330.71% Increased by +92.37% |
| Dec 31, 24 | 29.66 M Increased by +4.25 K% | -74.45 M Increased by +6.43% | Decreased by -250.98% Increased by +97.85% |
| Sep 30, 24 | 16.35 M Increased by +N/A% | -85.58 M Decreased by -97.90% | Decreased by -523.34% Decreased by N/A% |
| Jun 30, 24 | 7.32 M Increased by +N/A% | -91.45 M Decreased by -123.23% | Decreased by -1.25 K% Decreased by N/A% |
| Mar 31, 24 | 1.91 M Increased by +N/A% | -82.85 M Decreased by -119.10% | Decreased by -4.33 K% Decreased by N/A% |
| Dec 31, 23 | 682.00 K Increased by +N/A% | -79.57 M Decreased by -25.40% | Decreased by -11.67 K% Decreased by N/A% |